Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)

NCT02476006 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

998

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypercholesterolemia

Interventions

DRUG: ALIROCUMAB SAR236553 (REGN727)
DRUG: placebo (for injection training only)
DRUG: ezetimibe
DRUG: atorvastatin
DRUG: rosuvastatin
DRUG: simvastatin

Sponsor

Sanofi

Collaborators

[object Object]